These drugs slow gastric emptying, which can cause a prolonged sensation of fullness and a reduced desire to drink fluids
Patients with Hashimoto's thyroiditis starting GLP-1 therapy require thoughtful monitoring, though the presence of autoimmune thyroid disease does not necessitate fundamentally different safety protocols than for other patients
Early-cycle water retention typically subsides within 2 to 4 weeks
All orders have been seamless
Moreover, last year a separate study showed that 91% of obese individuals receiving a weekly dose of 15 mg Tirzepatidea recently developed GLP-1R/GIPR dual agonist, lost 5% of their body mass with 36% of participants on the same dosage losing at least 25% ( While these data are astoundingwith yearly progress in efficacy, we should consider that around 9% of patients receiving these game-changer treatments (Table 1)
Supply could not keep pace with fervent demand for the drug, which reached such dizzying levels of popularity that it transformed Novo Nordisk into one of the worlds most valuable companies, with a market capitalization larger than the rest of the economy of its home nation of Denmark